Addex Shareholders Approved all Board Proposals at Extraordinary General Meeting

Addex Secures Investor Commitment for CHF40 million Capital Increase Following Successful Completion of Book Building Process

Addex Publishes Extraordinary General Meeting Invitation

Addex Launches CHF40 million Capital Increase with Commitments from Specialist US Healthcare Investors

Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management

Addex Provides Key Financial Indicators and Trading Update

Van Leeuwenhoeck Issues Equity Research Note Highlighting Value of Recent Indivior Strategic Partnership on GABAB PAM

Addex Therapeutics Equity Research Report Update Issued by valuationLAB

Addex and Indivior Sign Strategic Partnership to Accelerate Development of GABAB PAMs as Addiction Treatments

Van Leeuwenhoeck Issues Initiation of Coverage Research Report on Addex Therapeutics and Estimated ADXN Share Price of CHF 11.5 per Share